Spring / Summer 2024 | The New Era 3
Our passionate and engaged community has been the heart of our work and the inspiration that motivates us since day one .
This bold approach , which we ’ ve spearheaded since our earliest days , led recently to several mergers of small biotech companies with larger pharmaceutical companies equipped to take the research further — proof that the strategy can , and will , pay off in advancing research . ( Read about these success stories on p . 10 .)
And in long-awaited news for those managing advanced symptoms , 2024 looks to be a year in which new formulations of levodopa and new ways to deliver it will secure FDA approval or make substantial progress in reviews . ( See p . 8 for more on these movements this year .)
For people and families with Parkinson ’ s , we know these advances cannot come soon enough . As Michael himself has said , it ’ s not a “ time-neutral situation ” to be living with PD . While this new era brings with it the promise of more breakthroughs , we remain sober about how much work lies ahead . And we remain committed to doing all we can to urgently lead the way .
We are steadfast in our mission , and as always , we will achieve it through your help . As our passionate and engaged community , you have always been the heart of our work and the inspiration that motivates us since day one . That has never been more true than right now , as we ask ourselves , “ What now ? What ’ s next ?”
Thank you for your support in this transformed new world . We are grateful to have you with us as we work toward the promise of better treatments and a cure for everyone living with Parkinson ’ s .
With gratitude ,
Debi Brooks , CEO and Co-Founder